Author
Listed:
- Lauren Hirsch
(University of Calgary
University of Calgary
University of Calgary)
- Jaeun Yang
(University of Calgary)
- Lauren Bresee
(University of Calgary
University of Calgary
Canadian Agency for Drugs and Technologies in Health)
- Nathalie Jette
(University of Calgary
University of Calgary
University of Calgary
University of Calgary)
- Scott Patten
(University of Calgary
University of Calgary
University of Calgary
University of Calgary)
- Tamara Pringsheim
(University of Calgary, Mathison Centre for Mental Health Research and Education)
Abstract
Introduction There is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs. Objectives This review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users. Studies could examine the use of any SGA medication and any comparator group. Studies also needed to include at least one metabolic outcome such as type 2 diabetes mellitus, dyslipidemia, obesity, hypertension, or metabolic syndrome. Methods A systematic search process was used to identify studies for inclusion in this review. Included studies had to be population-based studies of users of any SGA medication with at least one reported metabolic outcome. Study quality was also assessed using the AMSTAR tool, and evidence was synthesized by both metabolic outcome and specific SGA medication. Results In total, 15 studies were included in this review. Type 2 diabetes mellitus was the most frequently reported outcome; clozapine and olanzapine were most strongly associated with type 2 diabetes mellitus. Evidence was mixed for a moderate association between type 2 diabetes mellitus and risperidone or quetiapine. Few studies examined other metabolic outcomes, and therefore it is difficult to estimate the true effect in the population. Discussion Population-based evidence for other SGAs and metabolic outcomes was limited. However, clozapine and olanzapine were consistently more strongly associated with metabolic adverse events than were other SGAs currently available.
Suggested Citation
Lauren Hirsch & Jaeun Yang & Lauren Bresee & Nathalie Jette & Scott Patten & Tamara Pringsheim, 2017.
"Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies,"
Drug Safety, Springer, vol. 40(9), pages 771-781, September.
Handle:
RePEc:spr:drugsa:v:40:y:2017:i:9:d:10.1007_s40264-017-0543-0
DOI: 10.1007/s40264-017-0543-0
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Min Jung Sun & Mi Heui Jang, 2020.
"Risk Factors of Metabolic Syndrome in Community-Dwelling People with Schizophrenia,"
IJERPH, MDPI, vol. 17(18), pages 1-13, September.
- Nicolaas Martens & Eline De Haeck & Evelyn Van De Vondel & Marianne Destoop & Kirsten Catthoor & Geert Dom & Kris Van Den Broeck, 2023.
"Physical Healthcare for People with a Severe Mental Illness in Belgium by Long-Term Community Mental Health Outreach Teams: A Qualitative Descriptive Study on Physicians’, Community Mental Health Work,"
IJERPH, MDPI, vol. 20(1), pages 1-12, January.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:40:y:2017:i:9:d:10.1007_s40264-017-0543-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.